This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB08983/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08983/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB08983/identifier/wikipedia/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08983
rdf:type
n3:Drug
n3:description
Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.
n3:group
approved
owl:sameAs
n11:DB08983
dcterms:title
Etofibrate
adms:identifier
n7:Etofibrate n12:DB08983 n13:D07187
n3:synonym
Etofibrate
n3:synthesisReference
U.S. Patent 4,028,369.
n3:IUPAC-Name
n4:271B61F3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B61F9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B61F8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B61F5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B61F6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B61F7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B61F1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B61EF-363D-11E5-9242-09173F13E4C5 n4:271B61F2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B61F0-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:C10AB09
n3:H-Bond-Acceptor-Count
n4:271B61FF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6200-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B61FA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B61FB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B61FD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B61FC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B61FE-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
31637-97-5
n3:Bioavailability
n4:271B6204-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6206-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6207-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6208-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6203-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6202-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6205-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B61F4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6201-363D-11E5-9242-09173F13E4C5